Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice

被引:61
|
作者
Acton, DS
Velthuyzen, D
Lips, CJM
Höppener, JWM
机构
[1] Univ Utrecht, Med Ctr, Dept Internal Med, NL-3508 GA Utrecht, Netherlands
[2] Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands
关键词
medullary thyroid carcinoma; multiple endocrine neoplasia type 2B; human RET transgenic mice;
D O I
10.1038/sj.onc.1203648
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple endocrine neoplasia type 2B (MEN 2B) is a familial cancer syndrome, in which the cardinal feature is medullary thyroid carcinoma (MTC), a malignant tumor arising from the calcitonin producing thyroid C-cells, MEN 2B is associated with a germline point mutation in the RET proto-oncogene, leading to a Met-->Thr substitution at codon 918 in the kinase domain, which alters the substrate specificity of the protein. we used the human calcitonin gene (CALC-1) promoter to generate transgenic mice expressing either the human RET oncogene with the MEN2B-specific 918 Met-->Thr mutation (CALC-MEN2B-RET) or the human nonmutated RET proto-oncogene (CALC-WT-AET) in the C-cells, At 20-22 months of age three out of eight CALC-MEN2B-RET transgenic founders presented with macroscopic bilateral MTC, In two founders nodular C-cell hyperplasia (CCH) was observed. Thyroid abnormalities were never observed in CALC-WT-RET transgenic mice or control non-transgenic mice analysed at this age. In some mice from established CALC-MEN2B-RET transgenic lines nodular CCH was observed from 8 months on whereas MTC was detected in 13% of mice from one CALC-MEN2B-RET line, from the age of 11 months on. These results show for the first time that the MEN2B mutation in the RET oncogene predisposes mice for MTC.
引用
收藏
页码:3121 / 3125
页数:5
相关论文
共 50 条
  • [1] Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice
    Dennis S Acton
    Danny Velthuyzen
    Cornelis JM Lips
    Jo WM Höppener
    Oncogene, 2000, 19 : 3121 - 3125
  • [2] Mutation of RET proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
    Migita, M
    Hiromatsu, Y
    Sato, M
    Yang, D
    Kameo, J
    Jimi, A
    Nonaka, K
    ENDOCRINE JOURNAL, 1997, 44 (04) : 559 - 565
  • [3] RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma
    Marsh, DJ
    Mulligan, LM
    Eng, C
    HORMONE RESEARCH, 1997, 47 (4-6) : 168 - 178
  • [4] De novo RET proto oncogene mutation in a patient with multiple endocrine neoplasia type 2B
    Chang, TJ
    Wu, SL
    Chang, TC
    Huang, SH
    Chang, TJ
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1999, 98 (10) : 692 - 697
  • [5] Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation
    Qi, Xiao-Ping
    Lin, Guo-Bing
    Chen, Bo
    Li, Feng
    Cao, Zhi-Lie
    Zheng, Wei-Hui
    Zhao, Jian-Qiang
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2021, 21 (03) : 554 - 560
  • [6] Medullary thyroid carcinoma and multiple endocrine neoplasia type 2
    Takami, H
    ENDOCRINE PATHOLOGY, 2003, 14 (02) : 123 - 131
  • [7] Multiple endocrine neoplasia type 2 and medullary thyroid carcinoma
    Raue, F.
    Frank-Raue, K.
    MONATSSCHRIFT KINDERHEILKUNDE, 2008, 156 (10) : 981 - +
  • [8] Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B
    Skinner, MA
    DeBenedetti, MK
    Moley, JF
    Norton, JA
    Wells, SA
    JOURNAL OF PEDIATRIC SURGERY, 1996, 31 (01) : 177 - 182
  • [9] Medullary thyroid carcinoma and multiple endocrine neoplasia type 2
    Hiroshi Takami
    Endocrine Pathology, 2003, 14 : 123 - 131
  • [10] Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome - Influence of the stage on the clinical course
    Leboulleux, S
    Travagli, JP
    Caillou, B
    Laplanche, A
    Bidart, JM
    Schlumberger, M
    Baudin, E
    CANCER, 2002, 94 (01) : 44 - 50